SonoThera Presents New Data at ASH 2025 Demonstrating Durable Factor VIII Expression Using Ultrasound Mediated Gene Delivery in Treating Hemophilia A

South San Francisco, CA, December 8, 2025 – SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will present new data at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9th in Orlando, Florida.

SonoThera’s oral presentation focuses on the safe delivery of DNA expression vectors to the liver in non-human primate (NHP) models using its proprietary RIPPLETM ultrasound mediated delivery technology. Study results demonstrated durable protein expression of up to 65% of normal circulating FVIII levels in the blood. RIPPLETM is being developed to enable broad, highly targeted biodistribution of diverse payload formats without size restriction, allowing for genetic medicines that can be re-dosed, and which are safe, well-tolerated, and cost-effective.

“These new, positive results only further build upon our promising data previously presented at ASH,” said Kenneth Greenberg, PhD, SonoThera CEO. “We continue to demonstrate UMD’s potential to safely, efficiently deliver an oversized payload to the liver resulting in high levels of functional FVIII expression. Where current approved therapies for Hemophilia A are limited by variable expression, unfavorable durability, and immunogenicity, UMD has, thus far, shown its ability to address these challenges, and we look forward to sharing this data.”